Singapore's CytoMed Therapeutics partners with Sengkang General Hospital for a Phase I clinical trial of injectable cartilage regeneration therapy using umbilical cord-derived mesenchymal stem cells.

CytoMed Therapeutics, a Singapore biopharmaceutical company, has diversified into regenerative medicine through a research collaboration with Sengkang General Hospital. They aim to develop an injectable cartilage regeneration therapy using umbilical cord-derived mesenchymal stem cells (UC-MSCs), which will undergo a Phase I clinical trial in Singapore. The trial is expected to be completed within two years.